Old antibiotic gets a second look for tough e. coli infections

NCT ID NCT07318584

Not yet recruiting Disease control Sponsor: Oregon Health and Science University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study will test whether the antibiotic cefotetan works as well as standard treatments for E. coli infections in the blood or urinary tract. About 84 hospitalized adults will be randomly assigned to receive cefotetan or usual care. The goal is to see if cefotetan can successfully treat the infection without the need for additional antibiotics.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cefotetan (an antibiotic)
What this could lead to: If successful, cefotetan could become a new treatment option for certain E. coli infections, potentially reducing the need for stronger antibiotics.
What could go wrong: This is a small, early-phase pilot study. It may not show a clear benefit over existing antibiotics, and results may not apply to all E. coli infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates